Presentations Eledon Corporate Presentation ALS Phase 2a Clinical Trial Update Presentation Eledon Pharmaceuticals R&D Day Presentation Publications Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, For The Prevention of Rejection In Kidney Transplant Tegoprubart for the treatment of patients with IgA nephropathy: a snapshot of emerging data from an ongoing trial A Phase 2 Safety and Tolerability Study of an Anti CD40L Antibody, AT-1501 in Adults with ALS